Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings.

ABSTRACT:

Background

ALK-positive lung cancers are known to have favorable responses with oral tyrosine kinase inhibitors. Lorlatinib is an approved treatment option post first and second-line ALK inhibitors and is now also in first line. We present a retrospective observational study of the safety and efficacy of patients receiving Lorlatinib in second-line and beyond.

Methods

We conducted a retrospective observational study of ALK-positive patients who received Lorlatinib post-progression or intolerance to initial therapy at the Medical Oncology department. The patients who were started on Lorlatinib between January 2018 to December 2019 were included. The patients underwent routine blood and radiological evaluation every two to three months.

Results

A total of 38 patients re

SUBMITTER: Kumar A 

PROVIDER: S-EPMC11523971 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature